27 April 2021: OIA response | Technology assessment report (TAR) for SGLT-2 inhibitors (modelled as empagliflozin)
27 April 2021
Dear [name and contact details withheld]
REQUEST FOR INFORMATION
Thank you for your request dated 26 March 2021 under the Official Information Act 1982 (OIA) for information relating to empagliflozin.
Is the TAR for [empagliflozin] available? I'm keen to get estimates of the health impact.
Please find PHARMAC’s Technology Assessment Report (TAR) for SGLT-2 inhibitor (modelled as empagliflozin) included with this response.
- TAR 382 SGLT 2 inhibitors for type 2 diabetes [PDF 3.7 MB]
TARs are detailed analyses of new pharmaceuticals. They are used to determine the cost-effectiveness of pharmaceuticals that we are being asked to fund.
Release of information under the OIA
Please note that PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).
We don't normally publish our TARs because of commercial sensitivity; however, we have released this TAR under the OIA with a small amount of information redacted as we consider this is necessary to:
- protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
- protect information which is subject to an obligation of confidence or which any person has been or could be compelled to provide under the authority of any enactment, where the making available of the information would be likely to prejudice the supply of similar information, or information from the same source, and it is in the public interest that such information should continue to be supplied (section 9(2)(ba)(i));
- enable PHARMAC to carry on, without prejudice or disadvantage, negotiations, including commercial negotiations (section 9(2)(j)).
As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Manager, Policy and Government Services